Jan Astermark
161 – 170 of 191
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2003
-
Mark
Monitoring the bioavailability of FEIBA with a thrombin generation assay
- Contribution to journal › Article
-
Mark
When to start and when to stop primary prophylaxis in patients with severe haemophilia.
- Contribution to journal › Article
-
Mark
Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay
- Contribution to journal › Article
- 2002
-
Mark
Antibodies to factor VIIa in patients with haemophilia and high-responding inhibitors.
- Contribution to journal › Article
-
Mark
Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen
- Contribution to journal › Article
-
Mark
The prognostic value of global haemostatic tests in the intensive care unit setting.
- Contribution to journal › Article
-
Mark
Unresolved issues in prophylaxis
- Contribution to journal › Article
- 2001
-
Mark
Complexes between activated protein C and protein C inhibitor measured with a new method: comparison of performance with other markers of hypercoagulability in the diagnosis of deep vein thrombosis
- Contribution to journal › Article
-
Mark
Symposium in memory of Professor Inga Marie Nilsson
- Contribution to journal › Published meeting abstract
-
Mark
The Malmo International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients
- Contribution to journal › Article